SCHEMBL25815888

SCHEMBL25815888

CCOC(=O)c1cc(Cl)n2ccnc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.44
CA12 O43570 2/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA7 P43166 2/20 0.44
CA9 Q16790 2/20 0.44
CA14 Q9ULX7 2/20 0.44
JMJD6 Q6NYC1 2/20 0.43
ALDH1A1 P00352 6/20 0.42
KDM4E B2RXH2 5/20 0.42
HPGD P15428 5/20 0.42
GLA P06280 2/20 0.42
GAA P10253 2/20 0.42
CYP2C19 P33261 3/20 0.42
CYP2C9 P11712 1/20 0.42
HSD17B10 Q99714 2/20 0.42
CYP1A2 P05177 2/20 0.41
CYP2D6 P10635 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27198611 0.80 ALDH1A1 (0.41) KMT2ACA12CA1CA2CA7
SCHEMBL18077082 0.78 ALDH1A1 (0.45) KMT2ACA12CA1CA2CA7
SCHEMBL21439276 0.77 TPMT (0.39) JMJD6ALDH1A1KDM4EMAPT
SCHEMBL27004607 0.77 JMJD6 (0.44) KMT2AJMJD6ALDH1A1KDM4EHPGD
SCHEMBL26678236 0.77 KDM4E (0.41) KMT2AJMJD6ALDH1A1KDM4EHPGD
SCHEMBL21291210 0.77 ALDH1A1 (0.41) KMT2ACA12CA1CA2CA7
SCHEMBL27004616 0.75 MAPK1 (0.42) KMT2AJMJD6ALDH1A1KDM4EHPGD
SCHEMBL19697726 0.75 ALDH1A1 (0.40) KMT2ACA12CA1CA2CA7
SCHEMBL19697666 0.75 ALDH1A1 (0.40) KMT2ACA12CA1CA2CA7
SCHEMBL556235 0.74 JMJD6 (0.51) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062416-A1 INHIBITORS OF KIF18A AND USES THEREOF ACCENT THERAPEUTICS INC (US) 2026-03-05 US disclosed
WO-2024035950-A1 INHIBITORS OF KIF18A AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2024-02-15 WO disclosed
WO-2024035950-A1 INHIBITORS OF KIF18A AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2024-02-15 WO disclosed
WO-2023125182-A1 PROPIONIC ACID DERIVATIVE AND MEDICAL USE THEREOF 海思科医药集团股份有限公司 2023-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062416-A1 INHIBITORS OF KIF18A AND USES THEREOF KIF18A, KIF18B, KIF5B KMT2A 478/4885CA12 2953/4885CA1 1892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.